Significance: Intakes of MUFAs and PUFAs were associated with a lower risk of CVD and death, whereas SFA and trans-fat intakes were associated with a higher risk of CVD.
The effects of vaccenic acid (VA) and cis-9,trans-11 conjugated linoleic acid (c9,t11-CLA), and industrially produced trans fatty acids (iTFAs), in the context of highly controlled diets (24 d each), on lipoprotein risk factors compared with a control diet were determined in this double-blind, randomized, crossover feeding trial in 106 healthy adults [mean ± SD age 47 ± 10.8 y; BMI 28.5 ± 4.0 kg/m 2 ; and LDL-cholesterol 3.24 ± 0.63 mmol/L]. Diets were designed to have stearic acid replaced with the following trans fatty acids (TFAs) isomers (percentage of energy): 0.1% mixed isomers of TFA (control), ∼3% VA, ∼3% iTFA, or 1% c9,t11-CLA. Total dietary fat (34% of energy) and other macronutrients were matched. Total cholesterol (TC), LDL-cholesterol, triacylglycerol, lipoprotein(a), and apolipoprotein B were higher after VA than after iTFA; HDL-cholesterol and apolipoprotein AI also were higher after VA. Compared with control, VA and iTFA both increased TC, LDL-cholesterol, ratio of TC to HDL-cholesterol, and apolipoprotein B (2-6% change; P < 0.05); VA also increased HDL-cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) (2-6% change; P < 0.05), whereas iTFA did not. c9,t11-CLA lowered triacylglycerol (P ≤ 0.01) and had no effect on other lipoprotein risk factors.
Significance: Tree nut intake lowers total cholesterol, LDL-cholesterol, ApoB, and triglycerides, and the major determinant of cholesterol lowering appears to be nut dose rather than nut type.
The effects of tree nuts (walnuts, pistachios, macadamia nuts, pecans, cashews, almonds, hazelnuts, and Brazil nuts) on blood lipids [total cholesterol, LDLcholesterol, HDL-cholesterol, and triglycerides], lipoproteins [apolipoprotein A1, apolipoprotein B (ApoB), and apolipoprotein B100], blood pressure, and inflammation (C-reactive protein) in adults aged ≥18 y without prevalent CVD were examined in this systematic review and meta-analysis. Mean differences between nut intervention and control arms were calculated, dose-standardized to one 1-oz (28.4 g) serving/d, by using inverse-variance fixed-effects meta-analysis. Sixty-one trials met eligibility criteria (n=2582). Interventions ranged from 3 to 26 wk. Nut intake (per serving/d) lowered total cholesterol (−4.7 mg/dL; 95% CI: −5.3, −4.0 mg/dL), LDL-cholesterol (−4.8 mg/dL; 95% CI: −5.5, −4.2 mg/dL), ApoB (−3.7 mg/dL; 95% CI: −5.2, −2.3 mg/dL), and triglycerides (−2.2 mg/dL; 95% CI: −3.8, −0.5 mg/dL) with no statistically significant effects on other outcomes. The dose-response between nut intake and total cholesterol and LDL-cholesterol was nonlinear (P-nonlinearity < 0.001 each); stronger effects were observed for ≥60 g nuts/d. For ApoB, stronger effects were observed in populations with type 2 diabetes (−11.5 mg/dL; 95% CI: −16.2, −6.8 mg/dL) than in healthy populations (−2.5 mg/dL; 95% CI: −4.7, −0.3 mg/dL) (P-heterogeneity = 0.015).
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Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements D.J. McIver, A.M. Grizales, J.S. Brownstein, A.B. Goldfine Journal of Nutrition, Vol. 145, No. 12; pp. 2675 -2682 , 2015 Link to full text: Click here Significance: The odds of having type 2 diabetes were lower in those who, in the previous 30 days, had consumed supplements containing chromium.
This study examined the use and potential benefits of chromium supplementation in type 2 diabetes (T2D) by examining NHANES data. Data on all consumed dietary supplements from the NHANES database were analyzed, with the OR of having diabetes as the main outcome of interest based on chromium supplement use. The NHANES for the years 1999-2010 included information on 62,160 individuals. After filtering the database for the required covariates (gender, ethnicity, socioeconomic status, BMI, diabetes diagnosis, supplement usage, and laboratory glycated hemoglobin [HbA1c] values), and when restricted to adults, the study cohort included 28,539 people. A total of 58.3% of people reported consuming a dietary supplement in the previous 30 d, 28.8% reported consuming a dietary supplement that contained chromium, and 0.7% consumed supplements that had "chromium" in the title. Compared with nonusers, the odds of having T2D (HbA1c ≥6.5%) were lower in persons who consumed chromium-containing supplements within the previous 30 d than in those who did not (OR: 0.73; 95% CI: 0.62, 0.86). Supplement use alone (without chromium) did not influence the odds of having T2D (OR: 0.89; 95% CI: 0.77, 1.03).
This study prospectively examined the association between carbohydrates, starch, fibers, and different combinations of these nutrients and risk of type 2 diabetes (T2D) in 70,025 women free of cardiovascular disease, cancer, and diabetes at baseline from the Nurses' Health Study . During 1,484,213 person-years of follow-up, 6934 incident T2D cases were determined. In multivariable analyses, when extreme quintiles were compared, higher carbohydrate intake was not associated with T2D (RR=0.98; 95% CI: 0.89, 1.08), whereas starch was associated with a higher risk (RR=1.23; 95% CI: 1.12, 1.35). Total fiber (RR=0.80; 95% CI: 0.72, 0.89), cereal fiber (RR=0.71, 95% CI: 0.65, 0.78), and fruit fiber (RR=0.79; 95% CI: 0.72, 0.85) were associated with a lower T2D risk. The ratio of carbohydrate to total fiber intake was marginally associated with a higher risk of T2D (RR=1.09; 95% CI: 1.00, 1.20). Positive associations were found between the ratios of carbohydrate to cereal fiber (RR=1.28; 95% CI: 1.17, 1.39), starch to total fiber (RR=1.12; 95% CI: 1.02, 1.23), and starch to cereal fiber (RR=1.39; 95% CI: 1.27, 1.53) and T2D. This meta-analysis examined the effects of psyllium on glycemic control in patients who were being treated for type 2 diabetes mellitus (T2DM) and in patients who were at risk of developing T2DM. A comprehensive search was performed of available published literature and clinical records stored by Procter & Gamble with the use of key search terms to identify clinical studies that assessed the glycemic effects of psyllium in nondiabetic, pre-T2DM, and T2DM patients. Thirty-five randomized, controlled, clinical studies were identified that spanned 3 decades and 3 continents; the data were assessed in 8 meta-analyses. In patients with T2DM, multiweek studies (psyllium dosed before meals) showed significant improvement in both the fasting blood glucose (FBG) concentration (−37.0 mg/ dL; P < 0.001) and glycated hemoglobin (HbA1c) [−0.97% (−10.6 mmol/mol); P = 0.048]. Glycemic effects were proportional to baseline FBG; no significant glucose lowering was observed in euglycemic subjects, a modest improvement was observed in subjects with pre-T2DM, and the greatest improvement was observed in subjects who were being treated for T2DM.
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This cross-sectional study examined associations between living in specific census regions and frequency of sugar-sweetened beverage (SSB) consumption among US adults using 2010 National Health Interview Survey data (n=25,431). SSB consumption was defined as the consumption of four types of beverages (regular sugar-sweetened carbonated beverages, fruit drinks, sports/energy drinks, and sweetened coffee/tea drinks). The exposure variable was census region of residence (Northeast, Midwest, South, and West) . Approximately 64% of adults consumed SSBs ≥1 time/day. The odds of drinking SSBs ≥1 time/day were significantly higher among adults living in the Northeast (aOR=1.13; 95% CI=1.01, 1.26) but lower among adults living in the Midwest (aOR=0.70; 95% CI=0.64, 0.78) or West (aOR=0.78; 95% CI=0.71, 0.87) compared with those living in the South. The odds of drinking regular soda ≥1 time/day were significantly lower among adults living in the Northeast (aOR=0.51; 95% CI=0.45, 0.57), Midwest (aOR=0.86; 95% CI=0.78, 0.96), or West (aOR=0.56; 95% CI=0.51, 0.62) than those living in the South. The odds of drinking sports/energy drinks ≥1 time/day were significantly lower among adults living in the West (aOR=0.77; 95% CI=0.64, 0.93) than those living in the South. The odds of drinking a sweetened coffee/tea drink ≥1 time/ day were significantly higher among adults living in the Northeast (aOR=1.60; 95% CI=1.43, 1.78) but lower among adults living in the Midwest (aOR=0.70; 95% CI=0.62, 0.78) than those living in the South.
No Difference in Ad Libitum Energy Intake in Healthy Men and Women Consuming Beverages Sweetened With Fructose, Glucose, or High-Fructose Corn Syrup: A Randomized Trial J.N. Kuzma, G. Cromer, D.K. Hagman, K.L. Breymeyer, C.L. Roth, K.E. Foster-Schubert, et al. American Journal of Clinical Nutrition, Vol. 102, No. 6; pp. 1373 -1380 , 2015 Link to full text: Click here Significance: In healthy adults, total 8-d ad libitum energy intake was increased in individuals consuming sugar-sweetened beverages compared with aspartamesweetened beverages.
Two randomized, controlled, double-blind crossover studies were conducted to determine whether the relative amounts of fructose and glucose in sugar-sweetened beverages (SSBs) modifies ad libitum energy intake over 8 d in healthy adults without fructose malabsorption. Subjects consumed 4 servings/d of a fructose-, glucose-, or aspartame-sweetened beverage (study A; n = 9) or a fructose-, glucose-, or high-fructose corn syrup (HFCS)-sweetened beverage (study B; n = 24) for 8 d. SSBs were provided at 25% of estimated energy requirement, or an equivalent volume of the aspartame-sweetened beverage, and consumption was mandatory. All solid foods were provided at 125% of estimated energy requirements and were consumed ad libitum. In study A, ad libitum energy intake was 120% ± 10%, 117% ± 12%, and 102% ± 15% of estimated energy requirements when subjects consumed the fructose-, glucose-, and aspartame-sweetened beverages, respectively. Energy intake was significantly higher in the fructose and glucose phases than in the aspartame phase (P < 0.003 for each), with no difference between the fructose and glucose phases (P = 0.462). In study B, total energy intake during the fructose, HFCS, and glucose phases was 116% ± 14%, 116% ± 16%, and 116% ± 16% of the subject's estimated total energy requirements, respectively (P = 0.880).
This 2-part study investigated the effects of cocoa flavanol (CF) intake (amount and duration) on blood pressure, platelet function, metabolic variables, and potential adverse events (AEs) in healthy adults. Part 1 was an open-label, intake-amount escalation study, in which 34 healthy adults (aged 35-55 y) consumed escalating amounts of CFs, ranging from 1000 to 2000 mg/d over 6 wk. On the basis of the outcomes of study part 1, part 2 was a controlled, randomized, double-masked, 2-parallel-arm dietary intervention study in which healthy participants (aged 35-55 y) were asked to consume for 12 consecutive weeks up to 2000 mg CFs/d (n=46) or a CF-free control (n=28). Daily intake of up to 2000 mg CFs/d for 12 wk was not associated with significant changes in blood pressure or platelet function compared with CF-free controls in normotensive, healthy individuals who exhibited a very low risk of cardiovascular disease. There were no clinically relevant changes in the metabolic variables assessed in either of the groups. AEs reported were classified as mild in severity and did not significantly differ between study arms. 
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